Share
Journal Information
Most often read
61315
Anti-hepatitis B virus activity of food nutrients and potential mechanisms of actionAlexis Jose-Abrego, Ingrid Rivera-Iñiguez, Luis A. Torres-Reyes, Sonia Roman
Ann Hepatol. 2023;28:100766
61315
Full text access
17207
Intravenous albumin in cirrhosis: Updated clinical uses and novel perspectivesRoberta Gagliardi, Nicola Zeni, Salvatore Piano
Ann Hepatol. 2023;28:101150
17207
Full text access
15297
Liver diseases: Perspective from the PhilippinesEric David Ornos, Karl Jeffrey Murillo, Janus P. Ong
Ann Hepatol. 2023;28:101085
15297
Full text access
10936
A thorny matter: Spur cell anemiaRuchi Sharma, Carol J. Holman, Kyle E. Brown
Ann Hepatol. 2023;28:100771
10936
Open access
8057
What do we know about nutrient-based strategies targeting molecular mechanisms associated with obesity-related fatty liver disease?Ingrid Rivera-Iñiguez, Arturo Panduro, Sonia Roman, Karina González-Aldaco
Ann Hepatol. 2023;28:100874
8057
Open access
6457
New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLDLouise Torres, Alice Schuch, Larisse Longo, Bruna Bressan Valentini, Gabriela Schneider Galvão, Eduardo Luchese, Carlos Pinzon, Rodrigo Bartels, Mário Reis Álvares-da-Silva
Ann Hepatol. 2023;28:100774
6457
Open access
6056
Consensus document on acute-on-chronic liver failure (ACLF) established by the Mexican Association of HepatologyAldo Torre, Laura Esthela Cisneros-Garza, Mauricio Castillo-Barradas, Nalu Navarro-Alvarez, Ricardo Sandoval-Salas, María Sarai González-Huezo, José Luís Pérez-Hernández, Osvely Méndez-Guerrero, ... Francisco Alfonso Solís-Galindo
Ann Hepatol. 2023;28:101140
6056
Full text access
5223
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonistsLucy Gracen, Withma Muthukumara, Melanie Aikebuse, Anthony Russell, James O'Beirne, Katharine M. Irvine, Suzanne Williams, Gaurav Puri, ... Elizabeth E. Powell
Ann Hepatol. 2023;28:101142
5223
Full text access
4438
Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanismsXiaoyi Wang, Zhen Yang, Ying Ran, Long Li, Bangmao Wang, Lu Zhou
Ann Hepatol. 2023;28:101121
4438
Full text access
4140
Severe anemia is associated with increased short-term and long-term mortality in patients hospitalized with cirrhosisHaotang Ren, Hai Li, Guohong Deng, Xianbo Wang, Xin Zheng, Yan Huang, Jinjun Chen, Zhongji Meng, ... Yu Shi
Ann Hepatol. 2023;28:101147
4140
Full text access
3938
Immunotolerance in liver transplantation: a primer for the clinicianJuanita Pérez-Escobar, Jose Victor Jimenez, Erika Faride Rodríguez-Aguilar, Maximiliano Servín-Rojas, Jesus Ruiz-Manriquez, Luisa Safar-Boueri, Eduardo Carrillo-Maravilla, Miquel Navasa, Ignacio García-Juárez
Ann Hepatol. 2023;28:100760
3938
Open access
3537
Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agentsDiego García-Compeán, Ramesh Kumar, Ángel Noe del Cueto-Aguilera, Héctor Jesús Maldonado-Garza, Jesús Zacarías Villarreal-Pérez
Ann Hepatol. 2023;28:100751
3537
Full text access
3492
Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysisDaniela Contreras, Alejandra González-Rocha, Patricia Clark, Simón Barquera, Edgar Denova-Gutiérrez
Ann Hepatol. 2023;28:100873
3492
Open access
2922
Metabolic dysfunction: The silenced connection with fatty liver diseaseMariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez
Ann Hepatol. 2023;28:101138
2922
Full text access
2874
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysisMark Muthiah, Cheng Han Ng, Kai En Chan, Clarissa Elysia Fu, Wen Hui Lim, Darren Jun Hao Tan, Benjamin Nah, Gwyneth Kong, ... Mazen Noureddin
Ann Hepatol. 2023;28:100762
2874
Open access
2828
The treatment of diabetes in advanced liver disease: change of a paradigmMaria Letizia Petroni, Lucia Brodosi, Giulio Marchesini
Ann Hepatol. 2023;28:100772
2828
Open access
2687
Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective studyYongwu Chen, Xiuli Yang, Yanfei Shao, Hongying Zhao, Jinying Jiang, Ping Huang, Yi Lu, Zixue Xuan
Ann Hepatol. 2023;28:101099
2687
Full text access
2572
Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver diseaseJing Liu, Haifeng Lv, Jie Wang, Qianru Zhu, Gongying Chen, Yanming Jiang, Ke Zhao, Li Shao, ... Xiaoben Pan
Ann Hepatol. 2023;28:100892
2572
Full text access
2300
Validation of the Hepamet fibrosis score in a multi-ethnic Asian populationShi-En Chong, Felicia Chang, Kee-Huat Chuah, Pavai Sthaneshwar, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Wah-Kheong Chan
Ann Hepatol. 2023;28:100888
2300
Full text access
2216
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhoticsItamar Krispin, Mahmud Mahamid, Eran Goldin, Bashar Fteiha
Ann Hepatol. 2023;28:100897
2216
Full text access
Publish in
Annals of Hepatology
Affiliated societies
